There are currently 128 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are New York, Florida, California and Ohio.
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
NCT05853835
Recruiting
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/10/2024
Locations: AXIS Clinicals, Dilworth, Minnesota +1 locations
Conditions: Autoimmune Diseases, Multiple Sclerosis
Register for Updates
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
NCT05704361
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: Stanford University Medical Center; Stanford Neuroscience Health Center, Stanford, California +23 locations
Conditions: Multiple Sclerosis
Register for Updates
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
All
Ages:
Between 1 month and 99 years
Trial Updated:
06/07/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
Non-invasive BCI-controlled Assistive Devices
NCT05183152
Recruiting
Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems ba... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2024
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Register for Updates
Ketamine for MS Fatigue
NCT06064162
Recruiting
The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2024
Locations: Alta Bates Summit Medical Center, Berkeley, California
Conditions: Multiple Sclerosis
Register for Updates
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970
Recruiting
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medicati... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Register for Updates
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
NCT05735691
Recruiting
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
NCT04002934
Recruiting
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigatio... Read More
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/29/2024
Locations: Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
NCT02784210
Recruiting
Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not heal as well as others. Corticosteroids are the standard treatment to reduce symptoms of MS relapse. But there is no standard treatment for people with enhancing MS lesions without signs of M... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
05/15/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
NCT04933552
Recruiting
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
Gender:
Female
Ages:
All
Trial Updated:
05/14/2024
Locations: Novartis Investigative Site, La Jolla, California
Conditions: Multiple Sclerosis
Register for Updates
Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967
Recruiting
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Novartis Investigative Site, La Jolla, California
Conditions: Multiple Sclerosis, Pregnancy
Register for Updates
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatm... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2024
Locations: Yale School of Medicine, New Haven, Connecticut +11 locations
Conditions: Multiple Sclerosis
Register for Updates